Rafat Ansari - Concepedia

Author

Rafat Ansari

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Ansari, Rafat H., Helen J. Ross, Obasaju, Coleman K., R Ansari, R H Ansari, R. Ansari, R. H. Ansari, R.H Ansari, R.H. Ansari, Rafat Ansari

130

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Northern Indiana Cancer Research Consortium Hoosier Cancer Research Network (United States)University of Chicago Indiana University School of Medicine

About

Rafat Ansari is an author at Indiana University – Purdue University Indianapolis specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	45	2.1K
2	Health Sciences	15	19	686
3	Cell Biology	2	2	50
4	Social Sciences	1	1	37
5	Diagnostic Sciences	1	1	40

Rafat Ansari

Publications

Citations

H-Index

Page 1

	Year	Citations
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study Paulo M. Hoff, Rafat Ansari, Gerald Batist, Journal of Clinical Oncology	2001	1.1K
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer Nasser H. Hanna, Paul A. Bunn, Corey J. Langer, Journal of Clinical Oncology	2006	673
Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology Nasser H. Hanna, Marcus A. Neubauer, Constantin T. Yiannoutsos, Journal of Clinical Oncology	2008	492
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial Roy S. Herbst, Rafat Ansari, F. Bustin, The Lancet OncologyErlotinib Versus ErlotinibMedicineMetronomic TherapyBronchial Neoplasm	2011	391
Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401 Arti Hurria, Constance Cirrincione, Hyman B. Muss, Journal of Clinical Oncology	2011	343
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial Paul E. Goss, James N. Ingle, Kathleen I. Pritchard, Journal of Clinical Oncology	2013	258
Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203 Weijing Sun, Mark Powell, Peter J. O’Dwyer, Journal of Clinical Oncology	2010	216
Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial Gary R. Hudes, Lawrence H. Einhorn, Eric A. Ross, Journal of Clinical Oncology	1999	204
Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 Harvey B. Niell, James E. Herndon, Antonius A. Miller, Journal of Clinical Oncology	2005	187
Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer Nasser H. Hanna, Rogério Lilenbaum, Rafat Ansari, Journal of Clinical Oncology	2006	184

Page 1